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Objectives: Novel specialty biopharmaceuticals hold great promise for patients 
living with complex and chronic conditions. However, high research and develop-
ment costs, special handling, and other necessary enhancements to patient support 
programs all contribute to frequently higher prices for these products. This study 
sought to assess the value of specialty pharmaceuticals through an examination of 
the clinical, functional, and economic benefits of these treatments for the top three 
disease areas by pharmaceutical spend: rheumatoid arthritis (RA), multiple sclerosis 
(MS), and breast cancer (BC). MethOds: A systematic review of market research and 
cost-effectiveness articles was conducted for each disease area to assess clinical, 
functional, and economic outcomes associated with specialty medicine treatments 
versus the previous standard of care. Results: All RA clinical (ACR) and functional 
(HAQ) outcome articles were classified as positive. The median cost-effectiveness 
ratio was $37,000 per QALY. All MS clinical outcome (relapse rate) articles were posi-
tive. The MS functional outcome (EDSS) findings were less conclusive. The median 
cost-effectiveness ratio was $220,000 per QALY. The majority of BC articles yielded 
statistically inconclusive results for survival. All functional outcome (QLQ-C30) arti-
cles were positive. The median cost-effectiveness ratio was $49,000 per QALY. All 
endpoints reflect a population average treatment response and did not account for 
the presence of patient heterogeneity of treatment effect. cOnclusiOns: Novel 
specialty therapies hold great promise for arresting disease progression and improv-
ing quality of life for the three conditions associated with the highest specialty 
pharmaceutical spending. These findings demonstrate a strong value proposition 
for specialty pharmaceuticals in general, and suggest even greater substantial 
potential individual patient benefit with consideration of patient heterogeneity.
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bAckgROund: Herpes Zoster (HZ) or shingles, common among elderly people, 
increases with age and so does its severe outcomes including post herpetic neuralgia 
(PHN). Although efficacious in immunocompetent adults aged ≥ 50 years, protection 
from a licensed vaccine decreases in time which, faced with increasing disease risks, 
makes age of vaccination crucial. Objectives: To evaluate the cost effectiveness 
of HZ vaccination among adults aged ≥ 50 years and identify the public health and 
economically optimal vaccination age. MethOds: We used a cohort-based decision 
analysis model to compare the age-specific incidence, health care resource utiliza-
tion, costs and quality-adjusted life years (QALYs) related to HZ, PHN and non-pain 
complications among unvaccinated and vaccinated individuals at either age 50, 60 
or 70 years. Health outcomes, resource utilization and costs were projected for the 
US cohorts from 50 to 99 years of age. It incorporates HZ-specific QALY scores for 
duration and intensity of pain and the probabilities for Monte Carlo simulations. 
QALYs gained and cost per QALY gained from vaccination are the primary estimates. 
Sensitivity analyses were conducted on vaccine efficacy duration and other vari-
ables. Results: Vaccinating at age 60 would prevent more shingles cases (26,147 
cases per million persons) followed by vaccinating at age 70 while vaccinating at 
age 50 prevents the less number of shingles cases (21,269 vs. 19,795 respectively). 
However, vaccinating at age 70 would be the strategy with the biggest impact (8,055 
PHN cases prevented), followed by age 60 and then age 50 (4,055 vs. 1,012 PHN cases 
prevented, respectively). Vaccinating at age 70, 60, and 50 would societally cost 
$38,000, $80,000 and $272,000 per QALY saved, respectively. cOnclusiOns: Overall, 
the optimal age for vaccination would be at 70 years. While various uncertainties 
remain, our results were robust based on the sensitivity analyses and the magnitude 
of the differences in outcomes and costs between strategies.
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Objectives: To conduct an economic evaluation comparing a recombinant gonado-
trophin (r-hFSH, follitropin alfa, GONAL-f) with two classes of urinary gonadotro-
phins, hp-HMG (Menopur) and u-FSH (Fostimon) for ovarian stimulation in women 
undergoing in-vitro fertilization (IVF) treatment in The Netherlands MethOds: A 
pharmaco-economic model was developed, simulating each step in IVF protocol 
from start of therapy until either live birth, new IVF treatment cycle, or stopping 
IVF, following a long down-regulation protocol. A decision tree combined with a 
Markov model details progress through each health state, including oocyte retrieval, 
fresh embryo transfer, up to two subsequent cryo-embryo transfers, and (ongoing) 
pregnancy or miscarriage. A health insurer perspective was chosen and the time 
horizon was set to a maximum of three consecutive treatment cycles. Transition 
probabilities and costing data were derived from a real-world observational out-
comes database (Germany), and official tariff lists (The Netherlands). Adverse events 
were considered equal amongst comparators and therefore excluded. The model 
was validated by clinical experts to ensure appropriateness and to local manage-
ment of infertility and applicability. A Monte Carlo simulation with 5,000 iterations 
was undertaken for each strategy to explore uncertainty and to construct uncer-
tainty intervals (UI). Results: Mean total treatment costs were estimated as: € 5,664 
for GONAL-f (95%UI: € 5,167-€ 6,151), € 5,990 for Menopur (95%UI: € 5,498-€ 6,488) and 
€ 5,760 for Fostimon (95%UI: € 5,256-€ 6,246). The probability of a live birth was esti-
mated at 36.1% (95%UI: 27.4%-44.3%), 33.9% (95%UI: 26.2%-41.5%) and 34.1% (95%UI: 
25.9%-41.8%) for GONAL-f, Menopur and Fostimon respectively. Costs per live 
birth estimates are: € 15,674 (GONAL-f), € 16,878 (Fostimon) and € 17,636 (Menopur). 
Probabilistic sensitivity analysis indicates a probability of 72.5% that GONAL-f is 
cost-effective at a willingness-to-pay of € 20,000/live birth. Probabilistic results 
remained constant under several analyses. cOnclusiOns: GONAL-f appears to 
study was set; methods employed; the inclusion of active comparators; and study 
endpoints. Data was extracted from each study using a predefined data extraction 
form. Results: Seventy studies met our inclusion criteria and were included in 
our dataset. Many of these analyses’ have concluded that PET is cost-effective; 38% 
of the cost-effectiveness analyses’ findings indicate ICERs less than $50,000 (2012 
USD). Growth in the cost-effectiveness literature for PET parallels growth of the 
cost-effectiveness literature more broadly with 35% of studies published since 2009. 
Across all years, a smaller proportion of studies examining PET emanated from the 
US than did cost-effectiveness analyses generally (29% vs. 42%). The majority of 
studies examined PET for oncological indications (n= 58; 83%). The most common 
analytical method employed was cost-effectiveness analysis, although two cost-
minimization studies were also identified. Studies typically compared PET to either 
x-ray computed tomographic imaging or usual care. Diagnostic accuracy was the 
most common unit of effectiveness reported. cOnclusiOns: There is substantial 
literature evaluating the cost-effectiveness of PET across a range of indications. Most 
studies have examined diagnostic accuracy and not considered endpoints, such as 
how PET imaging influences clinical decision making or changes patient outcomes.
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Objectives: Centralizing city-wide neonatal total parenteral nutrition (TPN) pro-
duction can reduce medication errors through standardized processes and order 
sets and pediatric pharmacist review. However, it is unclear if the benefits justify 
the cost. The purpose of this study was to determine the costs and benefits of cen-
tralizing city-wide multi-institution neonatal TPN production at a single pediatric 
institution. A second objective was to calculate the error reduction potential by 
centralizing neonatal TPN preparation. MethOds: We performed a cost-benefit 
analysis of neonatal TPN preparation in a large metropolitan area, comparing the 
direct medical costs and benefits of centralized preparation at a large, nonprofit 
tertiary care pediatric hospital by pediatric pharmacists vs. decentralized prepara-
tion at multiple large, nonprofit tertiary care adult hospitals by staff pharmacists. 
Costs of TPN production and courier service were obtained from institution data. 
Medication error rates and costs of errors were obtained from the literature. We 
took the pediatric hospital perspective for a 5-year horizon. A 3% discount rate was 
used. Single-variable sensitivity analyses of medication error costs and error rates 
were performed to test the stability of the outcomes. Results: In 2013 adjusted 
dollars, total costs over 5 years for TPN centralization was $2,028,374 vs. $2,668,398 
for decentralization, a cost savings of $640,024. The primary benefit of TPN centrali-
zation was a decrease in the TPN error rate from 0.075% to 0.050%. Including both 
the costs of TPN production and the costs associated with TPN errors, the net cost 
of TPN centralization was $3,488,374 vs. $4,858,398 for decentralization, a net cost 
savings of $ 1,370,024. TPN centralization remained cost beneficial throughout the 
sensitivity analysis. cOnclusiOns: Centralizing city-wide multi-institutional TPN 
production at a pediatric hospital has the potential to reduce medication errors and 
result in significant cost savings for all participating institutions.
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Objectives: Cost utility analysis (CUA) is the technique of choice for decision 
making, yet the elicitation of utilities in children poses significant challenges. The 
objectives were to examine trends over time and to investigate sources for util-
ity weights used in pediatric CUA. MethOds: The Pediatric Economic Database 
Evaluation (PEDE) Project http://pede.ccb.sickkids.ca/pede maintains a searchable 
database of pediatric economic evaluations published since 1980. Data on study 
characteristics are routinely collected from each citation, and health state descrip-
tions, utility weights, and utility sources are extracted for each CUA. Descriptive 
statistics were used to analyze study characteristics for all studies included in PEDE 
from 1980 to 2012. Results: The PEDE database includes 2,485 full comparative 
pediatric economic evaluations. Cost-effectiveness analyses (CEAs) represent 66% 
and CUAs 22% of studies. The proportion of CUAs has grown over time, from 0% in 
1980 to 54% in 2012, with an average annual growth rate of 30% since 2002. Before 
2004, CUAs constituted fewer than 15% of pediatric health economic evaluations. 
In 2009 CUAs overtook CEAs as the most common analytic technique. In contrast, 
cost-benefit analyses accounted for 27% of studies between 1980 and 1990 and 
this decreased to 2% in 2012. A total of 1,420 health states were described in 559 
CUAs published between 1980 and 2012, but only 60% included utility weights. The 
majority of these weights were derived from other published sources, including 
adult studies. cOnclusiOns: The volume of pediatric CUAs has grown significantly 
since 1980 and CUAs now surpass CEAs as the most common technique for child 
health economic evaluation. However, few CUAs elicit utilities prospectively and 
rely instead on other published studies of unknown quality. Improved methods 
for eliciting utilities for child health states and the creation of a repository of valid 
utility weights will contribute to higher quality pediatric CUAs for decision-making.
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screening may reduce the annual number of stillbirths by up to 2,900, neonatal 
deaths by up to 1,100, the annual incidence of congenital syphilis by up to 1,450 and 
avert up to 130,000 DALYs at an incremental annual direct medical cost of US$ 5.9 
million. The three relatively high prevalence countries of Brazil, Colombia and Haiti, 
account for over half of the total DALYs that could potentially be averted, whereas 
Chile and Cuba have already adopted universal screening. cOnclusiOns: Use of 
ICS tests for antenatal syphilis screening is highly cost-effective in low and middle 
income countries in Latin America. Antenatal programs should either expand access 
or maintain full access to syphilis screening using the ICS test.
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Objectives: Coffee (Coffea arabica) contains over 1,000 distinct molecular compounds 
and is one of the most widely consumed beverages worldwide. Epidemiologic stud-
ies have shown an inverse relationship between coffee consumption and all-cause 
mortality. This analysis aims to assess the cost-effectiveness of coffee from the 
perspective of the US consumer and payer. MethOds: A cohort life-table analysis 
was developed to model life-years (LYs) of US coffee consumers vs non-consumers 
over a lifetime horizon. Age- and gender-specific mortality rates were used to model 
survival outcomes. Relative risks of death by average coffee intake (cups/day) were 
obtained from a recent large, prospective US cohort study. Costs per cup were esti-
mated for home preparation and obtained from a national sample of low- and high-
cost vendors. Incremental analyses were conducted by cost, sex, and level of daily 
coffee consumption. Deterministic (DSA) and probabilistic (PSA) sensitivity analy-
ses were conducted. The model was validated by comparing life expectancy results 
to a model utilizing relative risks of cancer and chronic diseases based on coffee 
consumption. Results: Coffee increased undiscounted LYs in 1, 2-3, 4-5, and 6+ 
cup/day male (0.72, 1.23, 1.48, and 1.22) and female (0.53, 1.42, 1.77, 1.65) consumers, 
respectively, versus non-consumers. ICERs per discounted LY gained were $5,460, 
$11,326, $24,254 for males and $5,885, $8,910, $20,145 for females, respectively, for 
1, 2-3, and 4-5 cups/day consumption of home-prepared coffee; 6+ cups/day was 
strictly dominated. Consumption of 4-5 cups per day purchased from high-cost ven-
dors was not cost-effective, with ICERs > $50,000/LY-gained. DSA showed that coffee 
effectiveness in preventing death and coffee acquisition cost had the largest impact 
on ICERs. cOnclusiOns: In this analysis, coffee consumption was associated with 
increased LYs and was shown to be potentially cost-effective, especially if home-
prepared or purchased from low-cost vendors. Given the observational nature of the 
study data, further research is warranted to validate these findings.
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Objectives: Maternal Death (MD) is a health public issue in Mexico, the MD Ratio 
(MDR) is 43.2 deaths/100,000 newborns, the Post-Partum Hemorragea (PPH) repre-
sents the second cause of MD (23%), with a higher impact in mexican provinces with 
poor or limited blood products access. The purpose of this study was to estimate 
from the health service provider perspective, the cost-effectiveness in the use of 
Human Fibrinogen (HF) (Clottafact®) in the hematologic treatment of masive PPH 
during limited access of boold products (access after 20 minutes). MethOds: A 
decition tree was created to estimate the survival probabilities and costs of PPH 
under a limited blood product access scenario, the use of HF or the use of recom-
binant Factor VII alfa (Factor rVIIa). The effectiveness was obtained from literature. 
The costs were estimated throughout an expert consensus and were expressed in US 
Dollars (exchange rate 1USD/13.0 MXN). The CER and ICER were estimated per saved 
live and a probabilistic sensibility analysis was performed. Results: The average 
cost per treated patient with limited access to blood products was 12,350 USD, with 
HF was $13,182 USD wheras with Factor rVIIa it was $14,526 USD. The survival rate 
was 0.59, 0.98 and 0.93 respectively. The cost per saved life with limited treatment 
was $21,238 USD, with HF was $13,410 and with Factor rVIIa it was $15,552 USD. The 
acceptability curve shows that the use of HF is cost-effective in 65% to 85% of the 
cases with a $3,000 USD willingness to pay limit. cOnclusiOns: Human Fibrinogen 
represents the best treatment alternative for the PPH in Mexican provinces with 
poor access to blood products and it would significantly reduce the MDR in Mexico.
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BIRtH ContRol
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Objectives: The objective of the study was to assess the cost-effectiveness of 
hysteroscopic tubal sterilization (HTS) for permanent birth control, compared with 
laparoscopic tubal sterilization (LTS). MethOds: Cost effectiveness was addressed 
through an economic evaluation using a decision analytic model that compared 
the health benefits and resource expenditures associated with three alternative 
protocols: Calgary HTS protocol, Saskatchewan HTS protocol, and LTS. The analysis 
adopted a payer perspective and considered direct medical service costs to the 
Alberta health system, including costs of physician, hospital and confirmative 
diagnosis. The time horizon for the analysis considered costs from initial surgery 
to follow-up diagnosis up to 6 months post-surgery. Clinical and epidemiological 
data came from a review of literature and expert opinions. Cost data for LTS were 
primarily obtained from provincial administrative databases. Results: Both the 
be cost-effective compared to the most prominent comparators in management of 
infertility in The Netherlands.
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Objectives: This study aimed to evaluate the cost-effectiveness of LNG-IUS 13.5mg, 
a low-dose hormonal intrauterine contraceptive system for use up to 3 years, rela-
tive to the most commonly used oral contraceptive (OC) in Canada from a societal 
perspective. MethOds: A state-transition model was developed to assess the 
cost-effectiveness of LNG-IUS 13.5mg over 3 years in a cohort of 1,000 women of 
reproductive age (15-44 years). The comparator was a generic version of the 100 
mcg levonorgestrel and 20 mcg ethinyl estradiol OC. The model consisted of three 
mutually exclusive health states: initial contraceptive method, unplanned preg-
nancy (UP) due to contraceptive failure and subsequent contraceptive method, taken 
up following UP or due to discontinuation of the initial method. The subsequent 
contraceptive method was represented by a basket of market-weighted contracep-
tives. Contraceptive failure and discontinuation rates were taken from published 
literature, resource use was estimated from product monographs and unit costs 
were taken from standard Ontario and Quebec cost databases. Analysis from the 
societal perspective allowed the model to incorporate economic costs associated 
with missed work. The key model output was cost per UP avoided. Probabilistic 
sensitivity analyses (PSA) were performed. Results: LNG-IUS 13.5mg dominated 
the OC method, resulting in fewer UP (8 vs. 180) and lower total costs ($665,224 vs. 
$1,102,456), representing a savings of $437,232 over 3 years. Overall savings resulted 
from fewer UP and avoided costs associated with the uptake of the subsequent con-
traceptive method. PSA results indicated a high probability of dominance as all itera-
tions showed LNG-IUS 13.5mg to be more effective and less costly. cOnclusiOns: 
LNG-IUS 13.5mg is an effective contraceptive option that generates savings com-
pared to a generic OC.
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Objectives: Postpartum hemorrhage (PPH) is a leading cause of maternal death. 
Although the strong evidence showing the efficacy of oxytocin in preventing PPH, its 
use remains suboptimal. The Uniject injection system prefilled with oxytocin (OiU) 
has the potential advantage, due to its ease of use, to increase oxytocin coverage rates 
(OCR). This study objective is to evaluate the cost-effectiveness of OiU in Latin America 
(LAC). MethOds: We built an epidemiological model to estimate the impact of replac-
ing oxytocin in ampoules with OiU on the incidence of PPH, quality-adjusted life 
years (QALYs) and costs from a health care perspective. A systematic search for data 
on epidemiology and cost studies was undertaken. A consensus panel among LAC 
experts was performed to quantify the expected increase in OCR as a consequence 
of making OiU available. Deterministic and probabilistic sensitivity analyses were 
performed. Results: In the threshold analysis the minimum required increment in 
the OCR to make OiU a cost-effective strategy ranged from 1.3% in Suriname to 16.2% 
in Haiti. In more than 60% of the countries, the required increment was below 5%. OiU 
could prevent more than 40,000 PPH episodes annually in LAC. In 27% of the countries 
OiU showed to be cost saving. In the remaining 21 countries OiU was associated with 
a net cost increment ($ 0.005 to $0.780 2013 US dollars per delivery). OiU strategy 
ranged from being dominant to having an ICER of $ 9,454 per QALY gained. In the great 
majority of countries these ICERs were below one GDP per capita. cOnclusiOns: 
OiU was cost-saving or very cost-effective in almost all countries. Even if countries 
can achieve only small increases in OCR by incorporating OiU, this strategy could be 
considered an efficient use of resources. These results showed to be robust in the 
sensitivity analysis under a wide range of assumptions and scenarios.
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Objectives: Untreated syphilis in pregnancy is associated with adverse clinical 
outcomes to the infant. In Latin America, roughly three out of every ten women 
are not tested for syphilis during pregnancy. The objective of this analysis was 
to evaluate the cost-effectiveness, budget impact, and potential reduction in 
adverse pregnancy outcomes of antenatal syphilis screening using the recently 
introduced point of care immunochromatographic strip test across 20 countries in 
Latin America. MethOds: A previously published cost-effectiveness model was 
adapted to reflect the perspectives of the respective national health care systems. 
Clinical outcomes of infants born to syphilis-infected mothers on the endpoints 
of stillbirth, neonatal death and congenital syphilis were obtained from published 
sources. Treatment was assumed to consist of three injections of benzathine penicil-
lin. Country-specific inputs included the antenatal prevalence of syphilis; annual 
number of live births; proportion of women with at least one antenatal care visit; 
per capita gross national income and estimated hourly nurse wages. Results: In 
all 20 Latin American countries, syphilis screening is highly cost-effective with an 
weighted average cost/DALY averted of US$110 (range: US$10-US$308). Universal 
